We have updated our Terms of Use.
Please read our new Privacy Statement before continuing.

Counting stars

5 April 2016 By Robert Cyran

The $160 bln deal is on the rocks after Treasury killed the tax rationale, erasing 15 pct of Allergan’s market value. A timely sale of its generic-drug business to Teva for $41 bln will cushion the blow and contain comparisons to Valeant. The financial flexibility is much needed.

This content is for Subscribers only


Email a friend

Please complete the form below.

Required fields *


(Separate multiple email addresses with commas)